Merck ' s Keytruda posts trial win in ' messy ' early NSCLC realm

As doctors weigh various immunotherapy strategies for the treatment of early-stage non-small cell lung cancer, Merck & Co. | As doctors navigate the "messy" early-stage non-small cell lung cancer landscape with various immunotherapy approaches, Merck & Co. has now unveiled new data that it hopes…#merckco
Source: Reuters: Health - Category: Consumer Health News Source Type: news